Neural Regeneration Research ›› 2021, Vol. 16 ›› Issue (12): 2388-2389.doi: 10.4103/1673-5374.313039

Previous Articles     Next Articles

Abnormal metal homeostasis as a common drug target to combat neurodegenerative diseases

Dagmar Pretsch*   

  1. Oxford Antibiotic Group GmbH, Konrad-Lorenz-Straβe, Tulln, Austria Department of Pharmacognosy, University of Vienna, Althanstrasse, Vienna, Austria 
  • Online:2021-12-15 Published:2021-05-13
  • Contact: Dagmar Pretsch, MSc, dagmar.pretsch@univie.ac.at or d.pretsch@oxfordantibioticgroup.com.
  • Supported by:

    The author thanks the Caenorhabditis Genetics Center for strains CL2120, CL2122, CL2659, and NL5901. I further thank Prof Dr Mark G Moloney FRSC FRACI FHEA from the Department of Chemistry at the University of Oxford and the company Oxford Antibiotic Group for their support.

PDF

103

Abstract: As life expectancy increases, the prevalence of age-related diseases will also increase. There has been an estimation that 50 million individuals are living with dementia in 2019. This number will increase to 75 million in 2030 and 131.5 million by 2050 (McGill-Carter, 2020). Neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson´s disease (PD) and Huntington disease (HD) disproportionately affect older adult populations, inflicting a considerable physical, emotional, and economic burden.